Simethicone can be injected into the abdomen 5cm outside the umbilicus to the waist for injection. 1. Simeglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog for adults with type 2 diabetes mellitus; it can be used in patients with unsatisfactory glycemic control after receiving metformin or sulfonylureas on the basis of dietary control and exercise; it can also be used to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus with concomitant cardiovascular disease. 2. Simethicone can be injected subcutaneously from 5cm outside the umbilicus of the abdomen to the lumbar region, avoiding repeated injections at the same site, avoiding injections where there are pits, thickening, scarring, ulceration, or lumps in the skin, and it can be injected in the thighs or the upper arms, and changing the injection site does not require any dosage adjustment. However, simepaglutide injection should not be injected intravenously or intramuscularly. 3. Simethicone Injection may cause hypoglycemia, gastrointestinal reactions (nausea, vomiting, diarrhea, etc.), acute pancreatitis, complications of diabetic retinopathy, injection site reactions (erythema, rash may appear at the injection site). Patients who need to use Simeglutide Injection for treatment should use the drug under the supervision of a physician.